Literature Search Results
Table 1 summarizes the key demographic characteristics of all trials previously done between the period of 1988 to 2020, including patients with diabetes. Five trials were eligible out of 13 trials which included only patients with diabetes for the analysis to rule out the efficacy of Aspirin for cardiovascular events. Table 2 summarizes the trials investigating the effect of Aspirin in the primary prevention of cardiovascular events and its risk of bleeding outcomes in individuals only with diabetes.
The present Meta-analysis comprised 23,570 diabetic patients; 11,738 allocated to Aspirin and 11,832 allocated to the control or placebo group.